Document Detail

Rethinking Phase II Clinical Trial Design in Heart Failure.
MedLine Citation:
PMID:  25343020     Owner:  NLM     Status:  Publisher    
The incidence and economic burden of heart failure continue to rise worldwide, despite implementation of a number of effective heart failure therapies. Although there have been a number phase I-II studies of potential novel heart failure therapies over the past decade, none of these new compounds have been successful in phase III clinical trials. While there are likely a number of reasons for this failure, one of the problems that has become increasingly apparent is the inability of phase II trials to correctly identify novel therapies that will be successful in phase III clinical trials. In the following review, we will discuss the some of the problems inherent with current phase II heart failure clinical trials, as well as discuss possible ways to rethink phase II development of new therapies for heart failure.
Kory J Lavine; Douglas L Mann
Publication Detail:
Journal Detail:
Title:  Clinical investigation     Volume:  3     ISSN:  2041-6792     ISO Abbreviation:  Clin Investig (Lond)     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2014-10-24     Completed Date:  -     Revised Date:  2014-10-25    
Medline Journal Info:
Nlm Unique ID:  101554582     Medline TA:  Clin Investig (Lond)     Country:  -    
Other Details:
Languages:  ENG     Pagination:  57-68     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Masking Release for Igbo and English.
Next Document:  Strategies for osteochondral repair: Focus on scaffolds.